Related Experiment Video

Updated: Nov 5, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.9K

Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A

Kun Huang1,2, Yingzi Zhen1,2, Gang Li2,3

  • 1Hematology Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|May 20, 2021
PubMed

Insights

Pharmacokinetic-guided prophylaxis optimizes treatment for severe hemophilia A by reducing bleeding episodes and infusion frequency. This personalized approach enhances patient quality of life through tailored factor VIII (FVIII) consumption.

Area of Science:

  • Hematology
  • Pharmacokinetics
  • Pediatric Medicine

Background:

  • Traditional weight-based dosing for hemophilia A can lead to suboptimal treatment due to pharmacokinetic variability.
  • Pharmacokinetic (PK)-guided prophylaxis offers a potentially optimized therapeutic strategy.

Purpose of the Study:

  • To evaluate the clinical outcomes of PK-guided prophylaxis in boys with severe hemophilia A.
  • To assess the impact of PK-guided dosing on bleeding rates and factor VIII consumption.

Main Methods:

  • Forty-six boys with severe hemophilia A received PK-guided prophylaxis.
  • PK parameters were assessed using a five-point assay and WinNonlin software.
  • Dosing adjustments were based on PK evaluation, bleeding history, and patient/physician recommendations.

Main Results:

  • PK-guided prophylaxis led to reduced annual bleeding rates (ABR), annual joint bleeding rates, and annual spontaneous bleeding rates (ASBR) in patients with adjusted dosing.
  • Patients with higher adjusted trough levels showed increased dose and frequency, alongside improved bleeding metrics.
  • No significant difference in ABR or ASBR was observed in patients with reduced trough levels, but infusion frequency and factor VIII (FVIII) consumption decreased.

Conclusions:

  • PK-guided prophylaxis optimizes hemophilia A treatment by reducing bleeds and factor VIII (FVIII) consumption.
  • This approach can decrease infusion frequency without increasing bleeding events, thereby improving patient quality of life.
Abstract

Keywords:
factor VIIIhaemophilia Apaediatricspharmacokineticsprophylaxis

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.8K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.1K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
71
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
58
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
49
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
49
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
40
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
45